Abstract:Recent studies indicated that oligomeric β -amyloid (A β) peptides are more neurotoxic to cells or tissues than A β monomers and fibrils even though the underlying mechanism of the A β -induced toxicity is still elusive. The discovery of inhibitors that can prevent cytotoxic oligomeric A β formation has become one of vital goals for therapeutic drug development for AD. Meanwhile, it is of fundamental importance to investigate and understand the structure of toxic A β oligomeric assembly, the mechanism of the induced cytotoxicity, the inhibitory mode of action, and the structural-activity relationship of inhibiting amyloid oligomerization. Toward this end, a series of 15 novel cyanine-derived A β peptide aggregation inhibitors have been synthesized aiming at investigating the structural-activity properties of these compounds in the role of AD treatment. Fifteen novel carbazole-based cyanine derivatives bearing various functionalized heteroaromatic electron-accepting moieties including pyridinium, benzothiazolium, quinolinium and acridinium have been synthesized for a systematic structure-activity relationships investigation as useful and potent A β peptide aggregation inhibitors. The binding affinity was characterized by dissociation constants derived from fluorescence titration of cyanine compounds against amyloid full-length A β 1-40, A β 1-42 peptides as well as A β fragments of different regions. The inhibitory effect on A β peptide aggregation was investigated with fluorescence, and transmission electron microscopy, and circular dichroism. The bio-viability was evaluated by cell-based and animal studies. Our studies further affirmed the importance of hydrophobic and Ï€-Ï€ stacking interactions for the association of this class of carbazole-based cyanines with A β peptides and fibrils. Slight structural modification alters the binding affinity to the monomeric and aggregated amyloids and hence the inhibition potency. Fifteen newly designed cyanine derivatives for studying the structural/activity properties of the A β binding and A β aggregation inhibition have been developed. Importantly, such slight structural variation also provides a means to tune the biological properties such as cytotoxicity and protection from A β- induced toxicity for potential clinical applications. Remarkably, seven non-toxic cyanine derived inhibitors for A β peptide self-aggregation are identified which shows therapeutic potential for AD treatment.

Rationally Designed Amyloid Inhibitors Based on Amyloid-Related Structural Studies

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Structure-Based Peptide Inhibitor Design of Amyloid-β Aggregation

Α-Helical Motif As Inhibitors of Toxic Amyloid-β Oligomer Generation Via Highly Specific Recognition of Amyloid Surface

Physicochemical Strategies for Inhibition of Amyloid Fibril Formation: an Overview of Recent Advances

Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.

Rational Design of an Orthosteric Regulator of Hiapp Aggregation

Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors

Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer's disease therapy

Peptides for Disrupting and Degrading Amyloids.

Structural mechanism for specific binding of chemical compounds to amyloid fibrils

Identification of Inhibitors for Amyloid-beta in Alzheimer's Disease and Cerebral Amyloid Angiopathy

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Rational Design of TDP-43 Derived α-Helical Peptide Inhibitors: An In Silico Strategy to Prevent TDP-43 Aggregation in Neurodegenerative Disorders

POTENT INHIBITORS FOR OLIGOMERIC B-AMYLOID AGGREGATION

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.

A Computational Study of Self-Assembled Hexapeptide Inhibitors Against Amyloid-Β (aβ) Aggregation.

Design of amyloidogenic peptide traps